Researchers recreated a nearly forgotten yogurt recipe that was once was once common across the Balkans and Turkey -- using ants. Reporting in the Cell Press journal iScience on October 3, the team shows that bacteria, acids, and enzymes in ants can kickstart the fermentation process that turns milk into yogurt. The work highlights how traditional practices can inspire new approaches to food science and even add creativity to the dinner table.

"Today's yogurts are typically made with just two bacterial strains," says senior author Leonie Jahn from the Technical University of Denmark. "If you look at traditional yogurt, you have much bigger biodiversity, varying based on location, households, and season. That brings more flavors, textures, and personality."

Red wood ants (Formica species) can be found crawling through the forests of the Balkans and Turkey, where this yogurt-making technique was once popular. To better understand how to use these ants to make yogurt, the researchers visited co-author and anthropologist Sevgi Mutlu Sirakova's family village in Bulgaria, where her relatives and other locals remember the tradition.

"We dropped four whole ants into a jar of warm milk by the instruction of Sevgi's uncle and community members," recalls lead author Veronica Sinotte of the University of Copenhagen, Denmark. The jar was then tucked into an ant mound to ferment overnight. By the next day, the milk had started to thicken and sour. "That's an early stage of yogurt, and it tasted that way as well."

The researchers, who tested the yogurt during their trip, described it as slightly tangy, herbaceous, and having flavors of grass-fed fat.

Back in Denmark, the team dissected the science behind the ant yogurt. They found that the ants carry lactic and acetic acid bacteria. Acids produced by these bacteria help coagulate the dairy. One type of these bacteria was similar to that found in commercial sourdough.

The insects themselves also help in the yogurt-making process. Formic acid, which is part of the ant's natural chemical defense system, acidifies the milk, affects its texture, and likely creates an environment for yogurt's acid-loving microbes to thrive, say the researchers. Enzymes from the ant and the microbes work in tandem to break down milk proteins and turn milk into yogurt.

The researchers compared yogurts made with live, frozen, and dehydrated ants. Only live ants seeded the right microbial community, meaning they are best suited for yogurt making. However, the team found that caution was necessary to make sure the ant products were safe to consume: live ants can harbor parasites, and freezing or dehydrating ants can sometimes allow harmful bacteria to flourish.

To test out the contemporary culinary possibilities of ant yogurt, the team then partnered with chefs at Alchemist, a two-star Michelin restaurant in Copenhagen, Denmark, who gave the traditional yogurt a modern twist. They served guests several concoctions including yogurt ice-cream sandwiches shaped like an ant, mascarpone-like cheeses with a pungent tang, and cocktails clarified with a milk wash -- all inspired by ant yogurt and using the insect as a key ingredient.

"Giving scientific evidence that these traditions have a deep meaning and purpose, even though they might seem strange or more like a myth, I think that's really beautiful," says Jahn.

"I hope people recognize the importance of community and maybe listen a little closer when their grandmother shares a recipe or memory that seems unusual," says Sinotte. "Learning from these practices and creating space for biocultural heritage in our foodways is important."

Read more …Would you eat yogurt made with ants? Scientists did

Scientists at Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have shown for the first time that glioblastoma -- the deadliest form of brain cancer -- affects not just the brain but also erodes the skull, alters the makeup of skull marrow, and interferes with the body's immune response. Drugs intended to inhibit skull-bone loss made the cancer more aggressive, according to results published on October 3 in Nature Neuroscience.

"Our discovery that this notoriously hard-to-treat brain cancer interacts with the body's immune system may help explain why current therapies -- all of them dealing with glioblastoma as a local disease -- have failed, and it will hopefully lead to better treatment strategies," said the paper's corresponding author Jinan Behnan, Ph.D., assistant professor in the Leo M. Davidoff Department of Neurological Surgery and in the department of microbiology & immunology at Einstein, and a member of the National Cancer Institute (NCI)-designated MECCC.

According to the NCI, approximately 15,000 people are diagnosed with glioblastoma each year. The median survival of those who receive standard treatment of surgery, chemotherapy, and radiation is approximately 15 months.

A Matter of Marrow

As is true for many other bones, the skull contains marrow in which immune cells and other blood cells form. Dr. Behnan's research on glioblastoma and the skull was prompted by recent studies revealing extremely thin channels that connect the skull with its underlying brain, allowing molecules and cells to travel between the skull's marrow and the brain.

Dr. Behnan and colleagues used advanced imaging techniques on mice that developed two different types of glioblastomas. They found that the tumors caused skull bones to erode, especially along the sutures where skull bones fuse. Such erosions seem to be unique to glioblastoma and other malignant intracranial tumors, since they don't occur with strokes, other types of brain damage, or even other systemic cancers. Computerized-tomography (CT) images of patients with glioblastoma revealed that decreases in skull thickness were present in the same anatomic areas as in mice.

The skull erosions in the mice were found to have increased the number and diameter of the skull-to-bone channels. The researchers hypothesized that these channels might allow the glioblastoma to transmit signals to the skull marrow that could profoundly change its immune landscape.

A Tilt Towards Inflammation

Using single-cell RNA sequencing, the researchers found that glioblastoma had dramatically shifted the skull marrow's immune-cell balance in favor of pro-inflammatory myeloid cells -- nearly doubling the levels of inflammatory neutrophils, while nearly eliminating several types of antibody-producing B cells as well as other B cells.

"The skull-to-brain channels allow an influx of these numerous pro-inflammatory cells from the skull marrow to the tumor, rendering the glioblastoma increasingly aggressive and, all too often, untreatable," said study co-author E. Richard Stanley, Ph.D., professor of developmental and molecular biology at Einstein. "This indicates the need for treatments that restore the normal balance of immune cells in the skull marrow of people with glioblastoma. One strategy would be suppressing the production of pro-inflammatory neutrophils and monocytes while at the same time restoring the production of T and B cells."

Interestingly, and adding to evidence that glioblastoma is a systemic rather than local disease, the marrows of the skull and femur reacted differently to the cancer. Glioblastoma activated several genes in the skull marrow that boosted production of inflammatory immune cells; but in femur marrow, the cancer suppressed genes needed to produce several types of immune cells.

The researchers wondered if administering anti-osteoporosis drugs that prevent bone loss would affect skull-bone erosion, glioblastoma, or both. To find out, they gave mice with glioblastoma tumors two different drugs approved by the U.S. Food and Drug Administration for treating osteoporosis. Both drugs (zoledronic acid and denosumab) halted skull erosion -- but one of them (zoledronic acid) also fueled tumor progression in one type of glioblastoma. Both drugs also blocked the beneficial effects of anti-PD-L1, an immunotherapy drug that boosts levels of tumor-fighting T cells.

The Nature Neuroscience paper is titled "Brain Tumors Induce Widespread disruption of Calvarial Bone and Alteration of Skull Marrow Immune Landscape." Additional MECCC and Einstein authors include Abhishek Dubey, Biljana Stangeland, Imane Abbas, David Fooksman, Ph.D., Wade R. Koba, B.S., Jinghang Zhang, M.D., Benjamin T. Himes, Ph.D., Derek Huffman, Ph.D., Zhiping Wu, Rachel Welch, David Reynolds, B.S., Kostantin Dobrenis, Ph.D., Qinge Ye, Kevin Fisher, and Emad Eskandar, M.D. Other authors include Erika Yamashita, Yutaka Uchida and Masaru Ishii, at Osaka University, Osaka, Japan, Robert A. Harris at Karolinska Hospital Solna, Stockholm, Sweden, Gregory M Palmer at Duke University Medical Center, Durham, North Carolina, Olivia R. Lu and Winson S. Ho at University of California, San Francisco, CA, and Alexander F. Fiedler at German Rheumatism Research Center (DRFZ) and Freie Universität Berlin, Berlin, Germany.

Read more …Brain cancer that eats the skull stuns scientists

More Articles …